Samuel R. Denmeade, M.D.
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Pharmacology, Biochemistry, OncologyWebsite:
https://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/denmeade.htmlGoogle:
"Samuel Denmeade"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Annastasiah M. Mhaka | grad student | 2005 | Johns Hopkins |
| Saurabh Aggarwal | grad student | 2006 | Johns Hopkins |
| Aaron M. LeBeau | grad student | 2009 | Johns Hopkins |
| W. N. Brennen | grad student | 2011 | Johns Hopkins |
| Michael L. Manning | grad student | 2012 | Johns Hopkins |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kumar R, Mendonca J, Shetty A, et al. (2024) CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. Biorxiv : the Preprint Server For Biology |
| Wise DR, Pachynski RK, Denmeade SR, et al. (2024) A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer and Prostatic Diseases |
| Denmeade SR. (2024) Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302310 |
| Markowski MC, Taplin ME, Aggarwal R, et al. (2024) Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature Communications. 15: 14 |
| Mori JO, Elhussin I, Brennen WN, et al. (2023) Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews. Urology |
| Isaacs JT, Dalrymple SL, Antony L, et al. (2023) Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. The Prostate |
| Wang A, Lazo M, Lu J, et al. (2023) Liver fibrosis scores and prostate cancer risk and mortality in the Atherosclerosis Risk in Communities (ARIC) Study. Cancer Prevention Research (Philadelphia, Pa.) |
| Sena LA, Wang H, Denmeade SR. (2023) First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer. The Prostate |
| Denmeade SR, Sena LA, Wang H, et al. (2023) Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. The Oncologist |
| Shenderov E, De Marzo AM, Lotan TL, et al. (2023) Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nature Medicine |